Takeda Pharmaceutical Company L (TAK) Stock Price & How to Invest

Takeda Pharmaceutical is Japan's largest pharmaceutical company and a top-tier global drugmaker, with roughly JPY 4.6 trillion in trailing revenue concentrated in gastroenterology (Entyvio for inflammatory bowel disease), rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company scaled up dramatically through its 2019 acquisition of Shire, which added rare-disease and plasma assets but also loaded the balance sheet with debt that management has been steadily paying down (total debt was still about JPY 5.5 trillion at the June 2026 quarter end). Takeda trades in the US as an ADR under the ticker TAK while its primary listing is on the Tokyo Stock Exchange (4502).

The investment picture is defined by a patent-cliff transition. Vyvanse, a former blockbuster ADHD drug, has lost US exclusivity and generics have sharply cut its revenue, and Takeda's largest product, the IBD drug Entyvio, faces biosimilar competition later this decade. To offset this, management is leaning on cost discipline, a subcutaneous version of Entyvio, and a late-stage pipeline led by oveporexton (TAK-861), an oral orexin agonist for narcolepsy type 1. That drug has now moved from pipeline to product: branded Orzeyful, it launched in Japan and China in mid-October 2026, and Takeda says the US launch follows next month once DEA scheduling is complete.

Recent results have also turned up. In the quarter ended June 30, 2026 (fiscal first quarter of the year to March 2027), revenue was about JPY 1.22 trillion, up roughly 10 percent from a year earlier, with net profit of about JPY 113 billion. The ADR has rerated accordingly, closing at $19.64 on October 16, 2026, against a 52-week range of $12.99 to $19.89, for a market value of about $63 billion. The dividend yield has drifted down to about 3.2 percent as the price rose.

The central risk is that pipeline launches, above all Orzeyful (oveporexton), do not ramp quickly enough to replace the revenue lost from Vyvanse generics and, later, Entyvio biosimilars, leaving earnings and the dividend under pressure. Slow US uptake after the DEA-scheduled launch, payer pushback on price, or safety signals in broader use would hit the stock harder now that a 2026 rally has priced in some success. Regulatory or clinical setbacks on other late-stage assets would remove further growth pillars. The company still carries meaningful post-Shire debt (about JPY 5.5 trillion), and drug pricing pressure in the US and elsewhere weighs on the whole sector. For US holders, the ADR adds yen currency risk on top of company-specific execution risk, and reported statutory profit has been volatile due to impairments and one-time items, with the trailing twelve-month statutory figure showing a net loss on Yahoo Finance data.

3 analysts publish price targets on TAK, averaging $22.75 against a $19.67 price as of October 2026, or +15.7%. The published targets run from $21.05 to $25.14, a narrow spread, and the ratings split 3 buy, 0 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full TAK forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Takeda Pharmaceutical Company L. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Oveporexton launch and the late-stage pipeline. Oveporexton (TAK-861), a first-in-class oral orexin receptor 2 agonist for narcolepsy type 1, met all endpoints in two registrational Phase 3 studies and won FDA Priority Review in February 2026. The most optimistic published target, $25.14, assumes this works close to its best case.

The case against. The central risk is that pipeline launches, above all Orzeyful (oveporexton), do not ramp quickly enough to replace the revenue lost from Vyvanse generics and, later, Entyvio biosimilars, leaving earnings and the dividend under pressure. The most pessimistic target, $21.05, is roughly what TAK is worth if this bites instead.

Read the full bull and bear case on TAK, including what would have to change to break either one. Walnut is not an investment adviser.

No. Takeda Pharmaceutical Company L (TAK) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Takeda Pharmaceutical Company L's investor relations page or your broker.

• Revenue (TTM): ~JPY 4.6T
• Revenue growth (latest quarter, YoY): ~+10%
• Operating margin (TTM): ~16%
• Net profit (June 2026 quarter): ~JPY 113B
• Market cap: ~$63B
• Share price (ADR, Oct 16 2026): ~$19.64
• Dividend yield: ~3.2%
• Trailing P/E: n/m (statutory TTM loss)

Revenue grew about 10 percent year over year in the June 2026 quarter, a better showing than the modest decline of the fiscal year to March 2026, and consensus looks for about JPY 4.7 trillion of revenue in the year to March 2027. A trailing P/E is not meaningful because impairments pushed statutory twelve-month profit below zero, so the market leans on core profit and cash flow, and the ADR's 42 percent one-year gain shows it has started to price in the oveporexton launch rather than only the patent cliff. The three analysts in Yahoo Finance's sample carry a mean target of about $22.76.

Other names that sit close to TAK: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get TAK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so TAK sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where TAK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Takeda is a mature, dividend-paying global pharma whose investment case hinges on whether its late-stage pipeline, now led by a launched oveporexton, can outrun the loss of exclusivity on its legacy franchises. The market has grown more willing to give it credit in 2026, with the ADR near its 52-week high going into fiscal second-quarter results on October 29.

Whether TAK is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TAK a buy or a sell?, and where the stock could go from here in the TAK stock forecast.

For income investors, whether TAK pays a dividend and how the payout looks is covered in does TAK pay a dividend? And to weigh TAK against a peer, read the full side-by-side comparisons: TAK vs PFE and TAK vs NVS.